3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Triple Negative Breast Neoplasms
2
Sarcoma
2
Recurrence
2
Neoplasms
2
Glioma
2
Wilms Tumor
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
32
Filgrastim
18
Irinotecan
15
Topotecan
14
Temozolomide
13
Vincristine
12
Peripheral Blood Stem Cell Transplantation
12
Granulocyte Colony-Stimulating Factor
12
Etoposide
12
Melphalan
11
fludarabine
10
Carboplatin
9
dinutuximab
8
Isotretinoin
8
Interleukin-2
8
Busulfan
8
humanized 3F8 anti-GD2 monoclonal antibody
7
aldesleukin
7
Doxorubicin
7
3-Iodobenzylguanidine
7
sargramostim
6
fludarabine phosphate
6
Vorinostat
6
Zoledronic Acid
5
Stem Cell Transplantation
5
Cisplatin
5
etoposide phosphate
4
Ipilimumab
4
Drug Therapy
4
ribociclib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neuroblastoma
×
CLR1404
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled